|
|
||||||||
B Activation




* Laboratory of Immunology, First Medical Clinic, and
Department of Immunology, University of Mainz, Mainz, Germany;
Gastroenterology Division, Brigham and Womens Hospital, Harvard Medical School, Boston, MA 02115; and
Department of Pathology and Anatomy, Eastern Virginia Medical School, Norfolk, VA 23507
The EBV-induced gene 3 (EBI3) is expressed in dendritic cells (DCs) and part of the cytokine IL-27 that controls Th cell development. However, its regulated expression in DCs is poorly understood. In the present study we demonstrate that EBI3 is expressed in splenic CD8, CD8+, and plasmacytoid DC subsets and is induced upon TLR signaling. Cloning and functional analysis of the EBI3 promoter using in vivo footprinting and mutagenesis showed that stimulation via TLR2, TLR4, and TLR9 transactivated the promoter in primary DCs via NF-
B and Ets binding sites at 90 and 73 bp upstream of the transcriptional start site, respectively. Furthermore, we observed that NF-
B p50/p65 and PU.1 were sufficient to transactivate the EBI3 promoter in EBI3-deficient 293 cells. Finally, induced EBI3 gene expression in DCs was reduced or abrogated in TLR-2/TLR4, TLR9, and MyD88 knockout mice, whereas both basal and inducible EBI3 mRNA levels in DCs were strongly suppressed in NF-
B p50-deficient mice. In summary, these data suggest that EBI3 expression in DCs is transcriptionally regulated by TLR signaling via MyD88 and NF-
B. Thus, EBI3 gene transcription in DCs is induced rapidly by TLR signaling during innate immune responses preceding cytokine driven Th cell development.
This article has been cited by other articles:
![]() |
M. El-behi, B. Ciric, S. Yu, G.-X. Zhang, D. C. Fitzgerald, and A. Rostami Differential Effect of IL-27 on Developing versus Committed Th17 Cells J. Immunol., October 15, 2009; 183(8): 4957 - 4967. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. Kempe, P. Heinz, E. Kokai, O. Devergne, N. Marx, and T. Wirth Epstein-Barr Virus-Induced Gene-3 Is Expressed in Human Atheroma Plaques Am. J. Pathol., July 1, 2009; 175(1): 440 - 447. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. Huber, V. Steinwald, A. Guralnik, A. Brustle, P. Kleemann, C. Rosenplanter, T. Decker, and M. Lohoff IL-27 inhibits the development of regulatory T cells via STAT3 Int. Immunol., February 1, 2008; 20(2): 223 - 234. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. Heidemann, C. Ruther, M. Kebschull, W. Domschke, M. Bruwer, S. Koch, T. Kucharzik, and C. Maaser Expression of IL-12-related molecules in human intestinal microvascular endothelial cells is regulated by TLR3 Am J Physiol Gastrointest Liver Physiol, December 1, 2007; 293(6): G1315 - G1324. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. Pirhonen, J. Siren, I. Julkunen, and S. Matikainen IFN-{alpha} regulates Toll-like receptor-mediated IL-27 gene expression in human macrophages J. Leukoc. Biol., November 1, 2007; 82(5): 1185 - 1192. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. F Neurath New therapies for sepsis: focus on the interleukin (IL)12 family member IL27 Ann Rheum Dis, November 1, 2007; 66(suppl_3): iii29 - iii31. [Abstract] [Full Text] [PDF] |
||||
![]() |
C. Molle, M. Nguyen, V. Flamand, J. Renneson, F. Trottein, D. De Wit, F. Willems, M. Goldman, and S. Goriely IL-27 Synthesis Induced by TLR Ligation Critically Depends on IFN Regulatory Factor 3 J. Immunol., June 15, 2007; 178(12): 7607 - 7615. [Abstract] [Full Text] [PDF] |
||||
![]() |
C. Becker, H. Dornhoff, C. Neufert, M. C. Fantini, S. Wirtz, S. Huebner, A. Nikolaev, H.-A. Lehr, A. J. Murphy, D. M. Valenzuela, et al. Cutting Edge: IL-23 Cross-Regulates IL-12 Production in T Cell-Dependent Experimental Colitis. J. Immunol., September 1, 2006; 177(5): 2760 - 2764. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. Wirtz, I. Tubbe, P. R. Galle, H. J. Schild, M. Birkenbach, R. S. Blumberg, and M. F. Neurath Protection from lethal septic peritonitis by neutralizing the biological function of interleukin 27 J. Exp. Med., August 7, 2006; 203(8): 1875 - 1881. [Abstract] [Full Text] [PDF] |
||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |